2 Reasons Why Nuance Communications Ate a Poison Pill

Before you go, we thought you'd like these...
Before you go close icon

Last week, Nuance Communications adopted a "poison pill," aimed at diluting the voting powers of any shareholder who acquires more than 20% of the company's shares outstanding.

Although the company claims the measure wasn't directed at any individual shareholder or company, the move is certainly a little suspicious, considering activist investor Carl Icahn recently built his position in Nuance to more than 16% of shares outstanding.

In the following video, Fool contributor Steve Heller gives two possible reasons for why Nuance "activated" this poison pill provision. Whatever the reason may be, it's become clear that the company is on the defensive.

The tech world has been thrown into chaos as the biggest titans invade one another's turf. At stake is the future of a trillion-dollar revolution: mobile. To find out which of these giants is set to dominate the next decade, we've created a free report called "Who Will Win the War Between the 5 Biggest Tech Stocks?" Inside, you'll find out which companies are set to dominate and give in-the-know investors an edge. To grab a copy of this report, simply click here -- it's free!

The article 2 Reasons Why Nuance Communications Ate a Poison Pill originally appeared on Fool.com.

Fool contributor Steve Heller owns shares of Nuance Communications. The Motley Fool recommends Nuance Communications. The Motley Fool owns shares of Nuance Communications. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners